Israeli biotechnology company Kadimastem has finalized an agreement with Hadassah Ein-Kerem Medical Center in Israel for conducting its first human stem cell therapy for the treatment of ALS. The therapy, called AstroRx, uses stem-cell-derived astrocytes, which are delivered intrathecally, to provide trophic support to degenerating motor neurons. Preclinical studies in ALS rat models have shown that the treatment prolongs survival in these models. Following consultation with the US FDA, the company will be conducting a Phase I/IIA safety and efficacy trial on 21 patients, to begin mid-2017.
Click here to read more.